Wuxi PharmaTech Hits Guidance Target

WuXi PharmaTech's financial results for 2009 highlight one of the major challenges facing the contract research and manufacturing services (CRAMS) sector. Despite achieving its publicly-stated revenue target, the Shanghai-based firm's share price fell by 8.3% to $14.50 in pre-market trading on the New York Stock Exchange.

To read the full article, please choose one of the following options: